Reviewing Mural Oncology (NASDAQ:MURA) & FutureWorld (OTCMKTS:FWDG)

FutureWorld (OTCMKTS:FWDG) and Mural Oncology (NASDAQ:MURA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Profitability

This table compares FutureWorld and Mural Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
FutureWorld	N/A	N/A	N/A
Mural Oncology	N/A	-70.10%	-61.30%

Analyst Ratings

This is a breakdown of current ratings and price targets for FutureWorld and Mural Oncology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FutureWorld	0	0	0	0	0.00
Mural Oncology	0	0	3	1	3.25

Mural Oncology has a consensus target price of $16.00, indicating a potential upside of 275.59%. Given Mural Oncology’s stronger consensus rating and higher probable upside, analysts plainly believe Mural Oncology is more favorable than FutureWorld.

Insider & Institutional Ownership

80.2% of Mural Oncology shares are owned by institutional investors. 0.1% of Mural Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares FutureWorld and Mural Oncology”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FutureWorld	N/A	N/A	N/A	N/A	N/A
Mural Oncology	N/A	N/A	-$207.45 million	($9.14)	-0.47

Summary

Mural Oncology beats FutureWorld on 6 of the 8 factors compared between the two stocks.

About FutureWorld

FutureWorld Corp., together with its subsidiaries, focuses on the identification, acquisition, development, and commercialization of hemp/cannabis products, services, and technologies worldwide. The company provides smart sensor technology, communication network, surveillance security, data analysis for smart cultivation, and consultation for the industrial hemp and legal medicinal marijuana. It offers personal and professional tetrahydrocannabinoil and Cannabidiol test kits; pharmaceutical grade CBD oil solutions; URVape vaporizer pens, which are oil vaporizers for the e-cigarette, cannabis, and herbal vaping industry; CaNNaLyTiX, a dashboard controller system that allows various computer systems to be integrated throughout a cultivator's infrastructures; CaNNaTRAK, the barcode and RFID tracking systems for keeping seed to sale tracking of hemp/cannabis; and SPIDer (secure perimeter intrusion detection network), a system to meet the needs of theft and malicious attacks. The company also provides SmartSense, which offers wireless security and smart sensor mesh network for precision agriculture, irrigation systems, and greenhouses for the hemp industry; SmartNergy that offers tools to analyze various aspects of a cultivator's energy usage; and CaNNaBoX machine, which operates with the swipe of a card to verify identity, age, and prescription information of a medical marijuana patient before releasing measured packages of marijuana. Its target customers include consumers via Internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, affiliate sales, and master distributors. The company was formerly known as FutureWorld Energy, Inc. and changed its name to FutureWorld Corp. in June 2014. FutureWorld Corp. was founded in 2002 and is based in Saint Petersburg, Florida.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.